#Taiwan #Japan #Tokyo #Be Health

BE Health Expands to Tokyo: A New Chapter in Healthcare Innovation

In response to the growing challenges presented by an aging population across Asia, the healthcare venture capital and accelerator, BE Health, has officially established its new base in Tokyo at the GLOBAL LIFESCIENCE HUB. This strategic move is set to enhance collaboration between hospitals and startups in Taiwan and Japan, aiming to accelerate the creation of innovative healthcare solutions.

A Bridge Between Taiwan and Japan

Founded in 2018 and headquartered in Taipei, BE Health uniquely combines hospital expertise, venture capital, and acceleration services. It has effectively connected over 170 startups across 19 countries in fields such as AI diagnostics, digital therapeutics, telemedicine, and precision imaging. This cross-border alliance seeks to address the critical question of how to create meaningful innovations that benefit clinical practice amid limited healthcare resources.

To celebrate its Tokyo launch, BE Health held an opening event titled "Beyond Borders: Taiwan-Japan Medtech Innovation Night" on October 2, 2025. The event served as a platform for professionals from both nations, including hospitals, investment firms, and startups, to exchange ideas and experiences. The event attracted over 70 experts, fostering lively discussions on collaborations between Taiwan and Japan.

Clinical Validation and Market Integration

One of the standout features of BE Health is its comprehensive support model that integrates clinical validation, regulatory compliance, and market launch. The company leverages the strengths of Taiwan's Shou-Chuan Medical Group and IRCAD Taiwan along with the international clinical network of Taipei Medical University. This synergy enables BE Health to guide startups through the intricate processes of validation and market entry.

Success Stories: Taiwan's Global Impact

The journey of Inopase, a startup emerging from the University of Tokyo's Japan Bio Design program, exemplifies BE Health’s successful approach. Since joining the accelerator, Inopase has secured funding from the Japan Agency for Medical Research and Development (AMED) and filed for eight patents within just two years. It has also advanced clinical trials in hospitals across Japan and Australia, marking a significant leap into the global market.

Another impressive case is Health2Sync, a digital AI chronic disease management platform originated in Taiwan. Health2Sync has transformed into Japan's largest digital chronic disease management solution, boasting over 700,000 users and partnerships with corporate health insurance organizations and multinational pharmaceutical firms.

These success stories not only display the robust international support framework established by BE Health and its partners but also reflect the strong anticipation for true innovations rooted in clinical settings. This focus on improving patients' lives resonates deeply within the Japanese market.

Collaborative Initiatives and Panel Discussions

During the Beyond Borders event, three sessions of panel discussions provided multifaceted insights into the challenges and solutions in launching Taiwan-based startups into the Japanese market. The first panel featured representatives from Tokyo University, Tohoku University Hospital, AIM Japan, and Dentall, who discussed the regulatory and ethical hurdles that Taiwanese startups face when entering Japanese hospitals.

The second panel included insights from Shou-Chuan Medical Group, Taipei Medical University, and Japanese startup Anaut, highlighting real-world experiences from proof of concept (PoC) to market deployment. They showcased how hospitals and accelerators work together to expedite startup growth.

The final session focused on cross-border agency agreements and licensing strategies, featuring participants from Teijin Pharma, OLBA Healthcare, and FREE Bionics. They delved into market entry insights and partnership building.

Moreover, the event featured a Pitch Rising Star competition, where five startups showcased innovative solutions addressing clinical needs. The pitches encompassed various groundbreaking technologies aimed at improving healthcare.

The winner, OUI, developed a smartphone-based ophthalmological tool that aims to reduce preventable blindness. Voting at the venue reflected the audience's recognition of clinical applicability and market potential, bringing attention to the possible innovations driven by the Taiwan-Japan healthcare collaboration.

Conclusion

As Be Health embarks on this new venture from its Tokyo base, it aims to not only serve as a hub for market expansion but also as a crucial bridge connecting Taiwanese and Japanese hospitals and international startups. The healthcare innovation landscape in Asia is evolving, welcoming a new era of cross-border cooperation that promises to address pressing clinical needs effectively.

Contact BE Health Tokyo Office: 103-0022 Tokyo, Chuo-ku Nihonbashi Muromachi 3-chome 2-1, Nihonbashi Muromachi Mitsui Tower 7F, GLOBAL LIFESCIENCE HUB.

About BE Health

BE Health is dedicated to fostering innovation in the medtech field. Our dual business models, BE Accelerator and BE Health Ventures, comprehensively support startups from development through to market entry. As Taiwan's largest medtech startup accelerator, we have guided over 150 startups with the help of around 100 mentors and have successfully raised over $20 billion in funding since our inception. BE Health Ventures focuses on investing in startups for sustainable growth.